- Home
- INFU vs FENC Comparison
INFU vs FENC Comparison
Compare INFU & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- FENC
- Stock Information
- Founded
- INFU 2005
- FENC 1996
- Country
- INFU United States
- FENC United States
- Employees
- INFU N/A
- FENC N/A
- Industry
- INFU Medical/Dental Instruments
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INFU Health Care
- FENC Health Care
- Exchange
- INFU Nasdaq
- FENC Nasdaq
- Market Cap
- INFU 189.2M
- FENC 156.9M
- IPO Year
- INFU N/A
- FENC 2001
- Fundamental
- Price
- INFU $8.12
- FENC $6.23
- Analyst Decision
- INFU
- FENC Strong Buy
- Analyst Count
- INFU 0
- FENC 2
- Target Price
- INFU N/A
- FENC $14.00
- AVG Volume (30 Days)
- INFU 72.9K
- FENC 61.2K
- Earning Date
- INFU 03-13-2025
- FENC 03-20-2025
- Dividend Yield
- INFU N/A
- FENC N/A
- EPS Growth
- INFU 60.96
- FENC N/A
- EPS
- INFU 0.07
- FENC N/A
- Revenue
- INFU $132,783,999.00
- FENC $49,348,000.00
- Revenue This Year
- INFU $10.23
- FENC $170.43
- Revenue Next Year
- INFU $8.80
- FENC $6.70
- P/E Ratio
- INFU $116.28
- FENC N/A
- Revenue Growth
- INFU 8.17
- FENC 278.09
- 52 Week Low
- INFU $5.74
- FENC $3.96
- 52 Week High
- INFU $9.97
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- INFU 48.91
- FENC 59.87
- Support Level
- INFU $7.86
- FENC $5.45
- Resistance Level
- INFU $8.25
- FENC $6.19
- Average True Range (ATR)
- INFU 0.28
- FENC 0.29
- MACD
- INFU 0.02
- FENC -0.01
- Stochastic Oscillator
- INFU 70.00
- FENC 85.71
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.